| Pair Name | Honokiol, Rapamycin | ||
| Phytochemical Name | Honokiol (PubChem CID: 72303 ) | ||
| Anticancer drug Name | Rapamycin (PubChem CID: 5284616 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Honokiol, Rapamycin | |||
| Disease Info | [ICD-11: 2C90.0] | Renal cell carcinoma | Investigative | |
| Biological Phenomena | Induction-->ROS generation | |||
| Gene Regulation | Down-regulation | Expression | CD274 | hsa29126 |
| In Vitro Model | 786-O | Renal cell carcinoma | Homo sapiens (Human) | CVCL_1051 |
| ACHN | Papillary renal cell carcinoma | Homo sapiens (Human) | CVCL_1067 | |
| Result | Honokiol can effectively overcome the limitation of Rapamycin treatment alone; and the combination treatment can markedly restrict the growth of RCC, with particular importance to post-transplantation renal cancer. | |||
| No. | Title | Href |
|---|---|---|
| 1 | A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune Escape. Cancers (Basel). 2020 Jul 3;12(7):1782. doi: 10.3390/cancers12071782. | Click |
